Related Experiment Video

Updated: Dec 27, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

563

Solute carrier proteins and c-Myc: a strong connection in cancer progression

Suman Panda1, Nilanjan Banerjee1, Subhrangsu Chatterjee1

  • 1Department of Biophysics, Bose Institute, P-1/12 CIT Road, Scheme VIIM, Kankurgachi, Kolkata, 700054, India.

Drug Discovery Today
|February 28, 2020
PubMed

Insights

Solute carrier proteins (SLCs) are crucial for cell metabolism and cancer progression. Targeting SLCs, especially in breast cancer linked to Myc oncogenes, offers new therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Cellular Metabolism
  • Oncology

Background:

  • Solute carrier proteins (SLCs) are vital membrane proteins regulating cellular homeostasis.
  • Dysregulation of SLCs is implicated in cancer development and progression.
  • SLCs are increasingly recognized as potential therapeutic targets in oncology.

Purpose of the Study:

  • To review the role of SLCs in cancer hallmarks.
  • To explore the link between the Myc oncogene and SLCs in breast cancer.
  • To discuss the potential of targeting glucose and amino acid transporters for cancer therapy.

Main Methods:

  • Literature review focusing on SLCs in cancer.
  • Analysis of the relationship between oncogenes (Myc) and SLCs.
  • Discussion of transporter roles in cancer cell metabolism.

Main Results:

  • SLCs play a significant role in various cancer hallmarks.
  • The Myc oncogene influences SLC expression in breast cancer.
  • Glucose and amino acid transporters are critical for cancer cell survival and proliferation.

Conclusions:

  • SLCs are key players in cancer biology and represent promising drug targets.
  • Understanding SLC-oncogene interactions, like Myc in breast cancer, is crucial for developing targeted therapies.
  • Manipulating SLCs involved in nutrient transport offers a viable strategy for novel anticancer treatments.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K